Group One Trading Adds $577K in AbCellera Biologics Inc. ($ABCL)
Key Points
- Group One Trading changed its AbCellera Biologics Inc. ($ABCL) stake by 85.4% last quarter, boosting to 239,133 shares worth $1.25 million.
- Wall Street's consensus rating on $ABCL is Strong Buy and an average price target of $10.43.
- $ABCL last traded around $5.24.
Group One Trading increased its position in AbCellera Biologics Inc. ($ABCL) by 85.4% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 239,133 shares of AbCellera Biologics Inc. after buying 110,134 shares during the quarter. Group One Trading's holdings in AbCellera Biologics Inc. were worth $1.25 million as of its most recent filing.
AbCellera Biologics Inc. ($ABCL) Stock
AbCellera Biologics Inc. Earnings
Analysts Set New Price Targets
About AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.